Botulinum Toxins

Joel L. Cohen MD, Director, AboutSkin Dermatology and DermSurgery (Greenwood Village and Lone Tree, Colorado); Associate Clinical Professor, University of Colorado Department of Dermatology, CO, USA, and; Assistant Clinical Professor, University of California Irvine Department of Dermatology, CA, USA David M. Ozog MD, Chair, Department of Dermatology, C.S. Livingood Chair of Dermatology, and Director of Cosmetic Dermatology, Henry Ford Hospital; Assistant Professor, Wayne State University, Detroit, MI, USA Dennis A. Porto MD, (Video Editor), Department of Dermatology, Henry Ford Hospital, Detroit, MI, USA

• List of Contributors   viiTreatment of the Periocular Area – Crow’s Feet, Brow, and Bunny Lines 165Girish S. Munavalli, MD (MHS, FACMS), Anthony V. Benedetto, DO (FACP, FCPP), Brian S. Biesman, MD (FACS), and Carolee M. Cutler Peck, MDAbout the Companion Website   xiii        Video Table of Contents   xv      1 History of Botulinum Toxin for Medical and Aesthetic Use 1     Alastair Carruthers, FRCPC and Jean Carruthers, MD (FRCS(C), FRCOphth)           2 Anatomy and Aesthetic Principles   13Timothy M. Greco, MD (FACS), Che´rie M. Ditre, MD, and David M. Ozog, MD (FAAD, FACMS)   3 Botulinum Toxin: From Molecule to Medicine 37           Conor J. Gallagher, PhD and Alan Ackerman, PhD            4 Myobloc   53Neil S. Sadick, MD (FACP, FAAD, FAACS, FACPh) and Suveena Manhas-Bhutani, MD       5 Abobotulinumtoxin: Development and Aesthetic Usage 65Gary D. Monheit, MD     6 IncobotulinumtoxinA (Xeomin®/Bocouture®)   79Ulrich Ku¨hne, MD (DALM) and Matthias Imhof, MD (DALM)      7  Future Injectable Toxins 97Michael H. Gold, MD      8 Reconstitution, Dilution, Diffusion, and Migration of Botulinum Toxin  109Murad Alam, MD (MSCI, MBA), Hayes B. Gladstone, MD, and David M. Ozog, MD (FAAD, FACMS)          9 Patient Selection 121Ryan M. Greene, MD (PhD, FACS), John P. Arkins, BS, and Steven H. Dayan, MD (FACS) 10 Treatment of the Glabella   133Neal D. Varughese, MD (MBA) and David J. Goldberg, MD (JD)  11  Treatment of the Forehead 147Joel L. Cohen, MD (FAAD, FACMS) and Ramin Fathi, MD12 Treatment of the Periocular Area - Crow's Feet, Brow and Bunny LinesGirish S. Munavalli, MD(MHS, FACMS), Antony V. BEnedetto, DO (FACP, FCPP), Brian S. Biesman, MD (FACS), and Carolee M. Cutler Peck, MD13 Contouring of the Lower Face and of the Lower Leg and Calf   177Mee young Park, MD (PhD), Dennis A. Porto, MD, and Ki Young Ahn, MD (PhD)                14  Treatment of the Perioral Area 191Shawn Allen, MD (FAAD, FACMS), Roberta Sengelmann, MD, and Rachel Simmons, MD (FAAD)                15 Neck Rejuvenation   199Koenraad De Boulle, MD, Lakhdar Belhaouari, MD, and Julia D. Kreger, MD         16  Correction of Facial Asymmetry 213Scott Rickert, MD (FACS), Lesley F. Childs, MD, and Andrew Blitzer, MD (DDS, FACS)         17  Complications and Diffusion   221Matteo C. LoPiccolo, MD, Farhaad R. Riyaz, MD, and David M. Ozog, MD (FAAD, FACMS)             18 Combination Therapy of Botulinum Toxin with other Nonsurgical Procedures 233Amy Forman Taub, MD and Lauren Fine, MD (FAAD)      19 Peri-Procedure Botulinum Toxin for Skin Cancer Patients and Scars   253Timothy Corcoran Flynn, MD, Molly C. Powers, MD, and David M. Ozog, MD (FAAD, FACMS)      20 Achieving a Natural Look   263Doris Hexsel, MD, Camile L. Hexsel, MD (FAAD, FACMS), and Carolina Siega, BSc                21 Special Considerations in Darker Skin   275Chere´ Lucas Anthony, MD and Marta I. Rendon, MD (FAAD, FACP)         22 Axillary Hyperhidrosis   285Ada Regina Trindade de Almeida, MD, Joel L. Cohen, MD (FAAD, FACMS), and Chinobu Chisaki, MD        23 Primary Focal Palm, Sole, Craniofacial, and Compensatory Hyperhidrosis 299Dee Anna Glaser, MD and Adam R. Mattox, DO (MS)     24  Topical Botulinum Toxin 317Richard G. Glogau, MD and Eileen Axibal, MD    25  Exciting New Uses of Botulinum Toxin Type A: Dermatology/Dermatologic Surgery and Beyond  329Donna Bilu Martin, MD (FAAD) and Stephen Mandy, MD (FAAD)              26 Modulating Affect and Mood with Botulinum Toxin Injections: Psychosocial Implications of Neuromodulators  345James L. Griffith, MD (MSci), Kevin C. Smith, MD (FRCPC (DERM)), and Murad Alam, MD (MSCI, MBA)   27  OnabotulinumtoxinA (Botox®) in Dermatology 357Jason J. Emer, MD, Eileen Axibal, MD, Ellen S. Marmur, MD (FAAD), and Heidi Waldorf, MD          Index 369